Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $164,400.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider owned 1,222,312 shares in the company, valued at approximately $20,094,809.28. This trade represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT traded down $0.77 during mid-day trading on Thursday, reaching $15.96. The stock had a trading volume of 2,074,092 shares, compared to its average volume of 1,985,070. Adaptive Biotechnologies Corporation has a twelve month low of $5.97 and a twelve month high of $20.76. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -29.56 and a beta of 2.18. The business has a 50 day simple moving average of $16.48 and a 200 day simple moving average of $14.25.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same quarter last year, the firm posted ($0.22) EPS. The business’s revenue was up 102.4% compared to the same quarter last year. As a group, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim assumed coverage on Adaptive Biotechnologies in a research report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Morgan Stanley began coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. BTIG Research boosted their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ameriprise Financial Inc. grew its position in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new position in Adaptive Biotechnologies in the 3rd quarter valued at about $14,934,000. First Trust Advisors LP increased its position in shares of Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after acquiring an additional 726,184 shares during the last quarter. Finally, Peregrine Capital Management LLC purchased a new stake in Adaptive Biotechnologies during the 2nd quarter worth approximately $8,187,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.